TX-COGNITE
9.1.2023 15:36:39 CET | Business Wire | Press release
Cognite, a global leader in industrial software, today announced four appointments to lead the company’s scaling efforts for its next stage of growth. Cognite's new executive leaders are Moe Tanabian, Chief Product Officer (CPO); Paul Lightfoot, SVP of User Experience; Emmanuelle Camus, President of Cognite EMEA; and Liat Berger, Chief Human Resources Officer (CHRO). These leaders held roles of increasing responsibility at Red Hat, Microsoft, Amazon, PTC, and Aker Solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230109005470/en/
L-R Liat Berger, CHRO; Moe Tanabian, CPO; Emmanuelle Camus, President EMEA; Paul Lightfoot, SVP UX (Photo: Business Wire)
Cognite’s CEO Girish Rishi said, "Building a high-performance team and developing our talent is a top priority. I'm pleased to welcome these leaders with diverse, global experiences, including deep technical skill sets and tenures at Fortune 500 companies. These accomplished executives will help us further scale our commitments to customers and partners as we solve the industrial data availability-to-value problem together."
Moe Tanabian, Cognite’s new Chief Product Officer, is charged with product strategy and execution, as well as product management, design, and engineering. He has been driving innovation at scale for nearly three decades, particularly in the areas of software products, AI, ML, and IoT. Tanabian recently served as Vice President and General Manager of Azure Light Edge for Microsoft, driving more than $2 billion P&L for Microsoft's portfolio of products in IoT, OT, and embedded industrial domains. Prior to his role at Microsoft, Tanabian worked for Samsung as Vice President of Smart Products and IoT, as well as Amazon, where he led the efforts to build and deliver the Amazon Android Appstore on Kindle Fire and Amazon Phone devices. Tanabian holds a master’s degree in Systems and Computer Engineering from Carleton University, Ottawa, Ontario and an MBA from the School of Business Queen’s University, Kingston, Ontario.
Liat Berger will serve as the new CHRO. She has a demonstrated track record of HR leadership with global multi-site companies and will help drive Cognite’s scale-up strategy. She has spent the last ten years at Aker Solutions and most recently served as Senior Vice President of People and Organization, Corporate, where she focused on business strategy by helping leaders identify, prioritize and build organizational capabilities, behaviors, and structures needed to support the change agenda. She also served as the Head of P&O for the Subsea Organization at Aker Solutions, which was composed of 4,500 employees distributed in 10 different locations on four different continents. Her expertise is building and balancing global companies while incorporating local realities, and she will play a key role in energizing Cognite’s global workforce. She is a graduate in Business Administration of Universidade Federal do Parana and has a specialization in Group Dynamics and People Management.
Emmanuelle Camus will assume the role of President of Cognite EMEA. She will focus on accelerating Cognite’s growth and strengthening the company’s position as a leading industrial software provider in the EMEA region in the Energy, Power, and Clean Tech and Manufacturing markets. Prior to joining Cognite, Camus spent 25 years at PTC in various leadership roles focused on business transformation and served most recently as their Senior Vice President of Alliances EMEAI. She has extensive experience in driving exponential growth in Europe & India through B2B sales and leveraging strategic alliances & partners and a strong background in solving Industry 4.0 challenges, digital transformation, Corporate Social Responsibility and Diversity, Equality & Inclusion. She is a graduate of NEOMA Business School.
Paul Lightfoot will support Tanabian as the new Senior Vice President of User Experience as Cognite doubles down on product design to allow customers to exponentially grow the number of data-literate industrial subject matter experts within their organizations. In his role, Lightfoot will lead Cognite's product design vision and strategy to meet these evolving needs as the OT industry is now being software-defined and is evolving into the fusing of physical and digital worlds at scale. Previously, he held product design leadership roles at several high-growth technology companies, most recently building out the product design/user experience practice at Red Hat as its Global Director, User Experience Product Design Team. Paul brings his passion for nurturing and developing a customer-obsessed culture to the role, as well as product management leadership and a focus on the discovery and development of product-market-fit. Paul has a degree in Management Information Systems from Bridgewater State University.
About Cognite
Cognite is a global industrial SaaS company that was established with a clear vision: to rapidly empower industrial companies with contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-heavy industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion®, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com and follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005470/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
